DFTX: DT120 100 mcg achieved rapid, durable efficacy in GAD with strong safety and long-term benefit
Panorama phase III results show DT120 100 mcg delivers rapid, robust, and durable efficacy in GAD, with a strong safety profile and consistent benefit across subgroups. Long-term data support sustained response and benefit from intermittent retreatment. NDA filing is planned for 2027.Based on Defin…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.